Bellevue Group’s Centessa Pharmaceuticals CNTA Stock Holding History

Bellevue Group’s Portfolio CNTA Stock Details CNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-9,030	Closed	-$359K	–	155
2026 Q1	$359K	Buy	+9,030	New	+$231K	0.01%	118

Bellevue Group's CNTA Position: Q2 2026 in Review

Bellevue Group sold out of Centessa Pharmaceuticals (CNTA) in Q2 2026, closing a stake of 9,030 shares — an estimated $359K sold.

Bellevue Group first reported a position in CNTA in Q1 2026 and held it in 1 quarter. The position peaked at $359K in Q1 2026. 0 funds tracked by Wall St. Rank hold CNTA as of Q2 2026.

Bellevue Group reported no remaining Centessa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Bellevue Group sold 9,030 Centessa Pharmaceuticals shares in Q2 2026, an estimated $359K.
Bellevue Group first reported a position in Centessa Pharmaceuticals in Q1 2026 and held it in 1 quarter.
Bellevue Group's Centessa Pharmaceuticals position peaked at $359K in Q1 2026.
0 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2026.

Based on Bellevue Group's 13F filing for Q2 2026, filed 14 Aug 2026.